You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
北大醫藥(000788.SZ):解熱鎮痛抗炎藥塞來昔布膠囊獲批上市
格隆匯 09-22 17:06

格隆匯9月22日丨北大醫藥(000788.SZ)公佈,近日,公司收到國家藥品監督管理局核准簽發的關於塞來昔布膠囊的《藥品註冊證書》。

塞來昔布是最新一代解熱鎮痛抗炎藥,批准用於緩解骨關節炎、類風濕性關節炎、成人急性疼痛以及強直性脊柱炎。產品對COX-2(環氧化酶2)具有高度選擇性並能特異性地抑制COX-2(對COX-1沒有抑制作用),可阻斷花生四烯酸合成前列腺素從而發揮抗炎鎮痛作用。塞來昔布的有效性與顯著的安全性已充分得到了臨牀和市場的認可,也是治療指南推薦用藥,其市場容量大。

塞來昔布因其較高的臨牀價值,未來市場前景良好,公司的塞來昔布膠囊獲批上市,進一步完善了公司在解熱鎮痛領域的產品結構,有利於提升公司在解熱鎮痛領域產品市場的競爭力,對公司未來業績的提升有積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account